In A375 melanoma cells, this spontaneous Rac1-driven resistance pathway is associated with an undifferentiated gene expression profile, activation of a YAP/TAZ gene expression signature, and resilience to pharmacological inhibition and genetic depletion of MEK1/2. The gene discussed is MAP2K1; the disease is melanoma.